Search Results - "Ipilimumab/administration & dosage"

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Authors: Decruyenaere, Alexander Gennigens, Christine Sylvie, Rottey et al.

Contributors: Decruyenaere, Alexander Gennigens, Christine Sylvie, Rottey et al.

Source: Acta Oncologica, Vol 64 (2025)
Acta oncologica
ACTA ONCOLOGICA

Subject Terms: Male, Immune Checkpoint Inhibitors/administration & dosage, Radiology, Nuclear Medicine and Imaging, Time Factors, Oncologie, THERAPY, Carcinoma, Renal Cell/secondary, immune checkpoint inhibitors, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Ipilimumab/administration & dosage, Human health sciences, Kidney Neoplasms/mortality, Immune Checkpoint Inhibitors, RC254-282, Aged, 80 and over, OUTCOMES, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Carcinoma, Renal Cell/pathology, Hematology, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Kidney Neoplasms, Progression-Free Survival, Renal cell carcinoma, Nivolumab/administration & dosage, treatment discontinuation, Carcinoma, Renal Cell/mortality, Kidney Neoplasms/drug therapy, Nivolumab, optimal treatment duration, Oncology, Female, Life Sciences & Biomedicine, Adult, DISCONTINUATION, Sciences de la santé humaine, Kidney Neoplasms/pathology, Immune Checkpoint Inhibitors/adverse effects, 3211 Oncology and carcinogenesis, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Carcinoma, Renal Cell, Retrospective Studies, Aged, Science & Technology, Duration of Therapy, Immune Checkpoint Inhibitors/therapeutic use, Ipilimumab, MELANOMA PATIENTS, Carcinoma, Renal Cell/drug therapy, Human medicine, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies

File Description: application/pdf

Access URL: https://doaj.org/article/f0b66be9934249d38e034df42f696b62
https://hdl.handle.net/2268/335276
https://doi.org/10.2340/1651-226X.2025.43876
https://repository.uantwerpen.be/docstore/d:irua:30312
https://hdl.handle.net/10067/2161490151162165141
http://hdl.handle.net/1942/46632
http://hdl.handle.net/1854/LU-01K3QQRTE94KZYP1CX1X0WZ5CD
https://biblio.ugent.be/publication/01K3QQRTE94KZYP1CX1X0WZ5CD/file/01K42SV66F3YD38FGWT899GJ86
https://biblio.ugent.be/publication/01K3QQRTE94KZYP1CX1X0WZ5CD
http://doi.org/10.2340/1651-226x.2025.43876

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Authors: Peters, Solange Paz-Ares, Luis G. Reck, Martin et al.

Contributors: Peters, Solange Paz-Ares, Luis G. Reck, Martin et al.

Source: Digital.CSIC. Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Journal of thoracic oncology, vol. 20, no. 1, pp. 94-108

Subject Terms: PD-L1, Nivolumab, Non–small cell lung cancer, Humans, Nivolumab/pharmacology, Nivolumab/therapeutic use, Nivolumab/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/mortality, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Lung Neoplasms/mortality, Lung Neoplasms/metabolism, Ipilimumab/pharmacology, Ipilimumab/therapeutic use, Ipilimumab/administration & dosage, Male, Female, Middle Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/metabolism, Aged, Adult, Survival Rate, Aged, 80 and over, Follow-Up Studies, Immunotherapy, Ipilimumab

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39369790
http://hdl.handle.net/10261/390933
https://api.elsevier.com/content/abstract/scopus_id/85208360083
https://serval.unil.ch/resource/serval:BIB_89D370D6F09D.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_89D370D6F09D
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_89D370D6F09D7

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Authors: Thierry André Elena Elez Eric Van Cutsem et al.

Source: New England Journal of Medicine
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)

Subject Terms: Adult, Aged, 80 and over, Male, Gastroenterology, Colorectal Neoplasms/drug therapy, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Hematology/Oncology, DNA Mismatch Repair, Ipilimumab, Progression-Free Survival, Nivolumab/administration & dosage, Young Adult, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Female, Microsatellite Instability, Ipilimumab/administration & dosage, Colorectal Neoplasms, Gastrointestinal Tract Cancer, Treatments in Oncology, Aged

Access URL: https://pubmed.ncbi.nlm.nih.gov/39602630
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14241

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Authors: N.M. Tannir L. Albigès D.F. McDermott et al.

Contributors: N.M. Tannir L. Albigès D.F. McDermott et al.

Source: Tannir, N M, Albigès, L, McDermott, D F, Burotto, M, Choueiri, T K, Hammers, H J, Barthélémy, P, Plimack, E R, Porta, C, George, S, Donskov, F, Atkins, M B, Gurney, H, Kollmannsberger, C K, Grimm, M O, Barrios, C, Tomita, Y, Castellano, D, Grünwald, V, Rini, B I, Jiang, R, Desilva, H, Fedorov, V, Lee, C W & Motzer, R J 2024, 'Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma : extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial', Annals of Oncology, vol. 35, no. 11, pp. 1026-1038. https://doi.org/10.1016/j.annonc.2024.07.727

Subject Terms: Male, Adult, Renal Cell/drug therapy, Medizin, long-term follow-up, Sunitinib/administration & dosage, dual checkpoint inhibition, Antineoplastic Combined Chemotherapy Protocols, Sunitinib, Humans, Ipilimumab/administration & dosage, ipilimumab, Carcinoma, Renal Cell, Aged, Carcinoma, advanced renal cell carcinoma, Middle Aged, phase III, Ipilimumab, CheckMate 214, Kidney Neoplasms, Progression-Free Survival, Nivolumab, ipilimumab, Nivolumab/administration & dosage, Kidney Neoplasms/drug therapy, Nivolumab, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies

Access URL: https://pubmed.ncbi.nlm.nih.gov/39098455

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Authors: Doki, Yuichiro Ajani, Jaffer A Kato, Ken et al.

Contributors: Doki, Yuichiro Ajani, Jaffer A Kato, Ken et al.

Source: Doki, Y, Ajani, J A, Kato, K, Xu, J, Wyrwicz, L, Motoyama, S, Ogata, T, Kawakami, H, Hsu, C H, Adenis, A, El Hajbi, F, Di Bartolomeo, M, Braghiroli, M I, Holtved, E, Ostoich, S A, Kim, H R, Ueno, M, Mansoor, W, Yang, W C, Liu, T, Bridgewater, J, Makino, T, Xynos, I, Liu, X, Lei, M, Kondo, K, Patel, A, Gricar, J, Chau, I, Kitagawa, Y & CheckMate 648 Trial Investigators 2022, ' Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma ', The New England Journal of Medicine, vol. 386, no. 5, pp. 449-462 . https://doi.org/10.1056/NEJMoa2111380

Subject Terms: Adult, Male, Squamous Cell/drug therapy, Immune Checkpoint Inhibitors/administration & dosage, Esophageal Neoplasms, B7-H1 Antigen/antagonists & inhibitors, B7-H1 Antigen, Carcinoma, Squamous Cell/drug therapy, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Ipilimumab/administration & dosage, Immune Checkpoint Inhibitors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carcinoma, CheckMate 648 Trial Investigators, Middle Aged, Ipilimumab, Survival Analysis, Progression-Free Survival, Nivolumab/administration & dosage, 3. Good health, Nivolumab, Squamous Cell, Carcinoma, Squamous Cell, Female, Esophageal Neoplasms/drug therapy

File Description: Print; application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/35108470
https://portal.findresearcher.sdu.dk/da/publications/76f3939c-aaec-43dc-b929-d332bb705979
https://discovery-pp.ucl.ac.uk/id/eprint/10143133/

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Authors: Owonikoko, Taofeek Park, Keunchil Govindan, Ramaswamy et al.

Contributors: Owonikoko, Taofeek Park, Keunchil Govindan, Ramaswamy et al.

Source: J Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
Journal of clinical oncology, vol. 39, no. 12, pp. 1349-1359

Subject Terms: Adult, Male, Lung Neoplasms, [SDV.IMM] Life Sciences [q-bio]/Immunology, Neoplasias pulmonares, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Otros calificadores::Otros calificadores::/uso terapéutico, Lung Neoplasms / drug therapy, Lung Neoplasms / mortality, Quimioteràpia combinada, 03 medical and health sciences, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma pulmonar de células pequeñas, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Double-Blind Method, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Ipilimumab / administration & dosage, Humans, Nivolumab / adverse effects, DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Small Cell Lung Carcinoma, Aged, Aged, 80 and over, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Mutación, Small Cell Lung Carcinoma / mortality, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, ORIGINAL REPORTS, Toxicidad, Middle Aged, Nivolumab / administration & dosage, Small Cell Lung Carcinoma / drug therapy, Ipilimumab, Small Cell Lung Carcinoma, 3. Good health, Nivolumab, Ipilimumab / adverse effects, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Supervivencia sin progresión, Female, Quimioterapia, Pulmons - Càncer - Tractament

File Description: application/pdf

Access URL: https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.02212
https://pubmed.ncbi.nlm.nih.gov/33683919
https://hdl.handle.net/11351/7760
http://hdl.handle.net/10668/17328
https://ascopubs.org/doi/10.1200/JCO.20.02212
https://europepmc.org/article/MED/33683919
https://profiles.wustl.edu/en/publications/nivolumab-and-ipilimumab-as-maintenance-therapy-in-extensive-dise
https://pubmed.ncbi.nlm.nih.gov/33683919/
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.02212
https://snucm.elsevierpure.com/en/publications/nivolumab-and-ipilimumab-as-maintenance-therapy-in-extensive-dise
https://serval.unil.ch/resource/serval:BIB_78F0D04B7BA3.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_78F0D04B7BA31
https://serval.unil.ch/notice/serval:BIB_78F0D04B7BA3
https://hdl.handle.net/10668/17328
https://inria.hal.science/hal-03526410v1
https://doi.org/10.1200/jco.20.02212

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

Authors: Tétu, P. Mangana, J. Dummer, R. et al.

Subject Terms: Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies, Humans, Ipilimumab/administration & dosage, Melanoma/drug therapy, Melanoma/pathology, Nivolumab/administration & dosage, Prognosis, Retrospective Studies, Survival Rate

Relation: European Journal of Cancer; https://iris.unil.ch/handle/iris/60408; serval:BIB_4C2D9AD34505; 000428617300018

Availability: https://iris.unil.ch/handle/iris/60408
https://doi.org/10.1016/j.ejca.2018.01.062

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

Authors: Pires da Silva, I. Ahmed, T. Reijers, ILM et al.

Subject Terms: Aged, Antibodies, Monoclonal, Humanized/administration & dosage, Humanized/adverse effects, Cohort Studies, Drug Resistance, Neoplasm/genetics, Neoplasm/immunology, Female, Humans, Immune Checkpoint Inhibitors/administration & dosage, Immune Checkpoint Inhibitors/adverse effects, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Male, Melanoma/drug therapy, Melanoma/genetics, Melanoma/immunology, Melanoma/pathology, Middle Aged, Neoplasm Metastasis, Nivolumab/administration & dosage, Nivolumab/adverse effects, Positron Emission Tomography Computed Tomography, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Programmed Cell Death 1 Receptor/genetics, Progression-Free Survival, Retrospective Studies

Relation: The Lancet Oncology; https://iris.unil.ch/handle/iris/43471; serval:BIB_001DC1DD3B64; 000657432100058

Availability: https://iris.unil.ch/handle/iris/43471
https://doi.org/10.1016/S1470-2045(21)00097-8

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Authors: Hellmann, M.D. Paz-Ares, L. Bernabe Caro, R. et al.

Subject Terms: Adult, Aged, 80 and over, Antineoplastic Agents, Immunological/administration & dosage, Immunological/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/metabolism, Carcinoma, Non-Small-Cell Lung/drug therapy, Non-Small-Cell Lung/metabolism, Non-Small-Cell Lung/mortality, Female, Humans, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Lung Neoplasms/drug therapy, Lung Neoplasms/metabolism, Lung Neoplasms/mortality, Male, Middle Aged, Nivolumab/administration & dosage, Nivolumab/adverse effects, Survival Analysis

Relation: New England Journal of Medicine; https://iris.unil.ch/handle/iris/202270; serval:BIB_9D16DE496DBE; 000505218800006

Availability: https://iris.unil.ch/handle/iris/202270
https://doi.org/10.1056/NEJMoa1910231

Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.

Authors: Schmid, S. Mauti, L.A. Friedlaender, A. et al.

Subject Terms: Adult, Aged, Antibodies, Monoclonal, Humanized/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Tumor/analysis, Female, Follow-Up Studies, Humans, Immunotherapy/mortality, Ipilimumab/administration & dosage, Lung Neoplasms/drug therapy, Lung Neoplasms/immunology, Lung Neoplasms/mortality, Lung Neoplasms/pathology, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Local/immunology, Local/mortality, Local/pathology, Nivolumab/administration & dosage, Prognosis, Retrospective Studies, Small Cell Lung Carcinoma/drug therapy, Small Cell Lung Carcinoma/immunology, Small Cell Lung Carcinoma/mortality

Relation: Cancer Immunology, Immunotherapy; https://iris.unil.ch/handle/iris/202157; serval:BIB_9C822C4B4241; 000527516900002

Availability: https://iris.unil.ch/handle/iris/202157
https://doi.org/10.1007/s00262-020-02565-0

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

Authors: Chalabi, M. Verschoor, Y.L. Tan, P.B. et al.

Subject Terms: Adult, Aged, 80 and over, Female, Humans, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Colonic Neoplasms/drug therapy, Colonic Neoplasms/genetics, Colonic Neoplasms/pathology, Colonic Neoplasms/surgery, Disease-Free Survival, DNA Mismatch Repair, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Ipilimumab/therapeutic use, Neoadjuvant Therapy, Nivolumab/administration & dosage, Nivolumab/adverse effects, Nivolumab/therapeutic use, Time-to-Treatment, Antineoplastic Agents, Immunological/administration & dosage, Immunological/adverse effects, Immunological/therapeutic use, Netherlands, Young Adult

Relation: New England Journal of Medicine; https://iris.unil.ch/handle/iris/174715; serval:BIB_6BBA7AFF15CD; 001265114100004

Availability: https://iris.unil.ch/handle/iris/174715
https://doi.org/10.1056/NEJMoa2400634

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.

Authors: Zezza, M. Kosinski, C. Mekoguem, C. et al.

Subject Terms: Acute Disease, Aged, 80 and over, Antineoplastic Agents, Immunological/administration & dosage, Immunological/adverse effects, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Diabetes Mellitus, Type 1/chemically induced, Type 1/diagnosis, Type 1/pathology, Female, Humans, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Male, Melanoma/drug therapy, Melanoma/pathology, Middle Aged, Nivolumab/administration & dosage, Nivolumab/adverse effects, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Autoimmune adverse events, Endocrinopathies, Immune checkpoint inhibitor, Type 1 diabetes

File Description: application/pdf

Relation: BMC Endocrine Disorders; https://iris.unil.ch/handle/iris/153712; serval:BIB_CB7AD473C23D; 000511656300001

Availability: https://iris.unil.ch/handle/iris/153712
https://doi.org/10.1186/s12902-019-0467-z

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Authors: Lebbé, Celeste Meyer, Nicolas Mortier, Laurent et al.

Source: J Clin Oncol
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998

Subject Terms: Adult, Male, Skin Neoplasms, Time Factors, Medizin, Antineoplastic Agents, Drug Administration Schedule, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Antineoplastic Agents, Immunological/administration & dosage, Double-Blind Method, Immunological/administration & dosage, Skin Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Melanoma/drug therapy, Ipilimumab/administration & dosage, Melanoma, Aged, Neoplasm Staging, Aged, 80 and over, 2. Zero hunger, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Ipilimumab, Progression-Free Survival, Nivolumab/administration & dosage, 3. Good health, Nivolumab, Disease Progression, Female, Rapid Communication

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/30811280
https://hdl.handle.net/20.500.12530/76708
https://pubmed.ncbi.nlm.nih.gov/30811280/
http://europepmc.org/article/MED/30811280
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.18.01998
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455714
https://ascopubs.org/doi/10.1200/JCO.18.01998
https://moh-it.pure.elsevier.com/en/publications/evaluation-of-two-dosing-regimens-for-nivolumab-in-combination-wi-3
https://curis.ku.dk/ws/files/236508642/jco.18.01998.pdf

Dose-dependent toxicity of ipilimumab in metastatic melanoma

Authors: Olischewsky, Alexandra De Schrijver, Sofie Bankfalvi, Agnes et al.

Contributors: Olischewsky, Alexandra De Schrijver, Sofie Bankfalvi, Agnes et al.

Source: European journal of cancer

Subject Terms: Male, 0301 basic medicine, Adolescent, Dose-Response Relationship, Drug, Maximum Tolerated Dose, Gastrointestinal Diseases/chemically induced, Medizin, Nivolumab/administration & dosage, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Unknown Primary/drug therapy, Skin Neoplasms/drug therapy, Humans, Melanoma/drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Ipilimumab/administration & dosage, Human medicine, Neoplasm Metastasis

Access URL: https://pubmed.ncbi.nlm.nih.gov/29477367/
https://www.ncbi.nlm.nih.gov/pubmed/29477367
https://hdl.handle.net/10067/1525460151162165141
https://hdl.handle.net/20.500.14017/c8c32dc5-c30f-478e-b1c5-9b680d7e38fe
https://biblio.vub.ac.be/vubir/dosedependent-toxicity-of-ipilimumab-in-metastatic-melanoma(c8c32dc5-c30f-478e-b1c5-9b680d7e38fe).html
https://doi.org/10.1016/j.ejca.2018.01.088
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85042186995
https://www.ncbi.nlm.nih.gov/pubmed/29477367
https://doi.org/10.1016/j.ejca.2018.01.088

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Authors: Motzer, Robert J. Tannir, Nizar M. McDermott, David F. et al.

Contributors: Motzer, Robert J. Tannir, Nizar M. McDermott, David F. et al.

Source: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
NEW ENGLAND JOURNAL OF MEDICINE
CheckMate 214 Investigators 2018, 'Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma', The New England Journal of Medicine, vol. 378, no. 14, pp. 1277-1290. https://doi.org/10.1056/NEJMoa1712126

Subject Terms: Anticuerpos Monoclonales, Male, Indoles, MULTICENTER, Supervivencia sin Enfermedad, Pyrrole, THERAPY, Antineoplastic Agents, Immunological, 0302 clinical medicine, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Medicine and Health Sciences, Sunitinib, Tasa de Supervivencia, Ipilimumab/administration & dosage, Masculino, Aged, 80 and over, Persona de Mediana Edad, KIDNEY CANCER, Adulto, Kidney Neoplasm, Antibodies, Monoclonal, PHASE-III TRIAL, Indoles/administration & dosage, General Medicine, Middle Aged, OPEN-LABEL, Kidney Neoplasms, Humanos, 3. Good health, Survival Rate, Kidney Neoplasms/drug therapy, Immunological, Nivolumab, Antineoplásicos Inmunológicos, Survival Analysi, Human, Protocolos de Quimioterapia Combinada Antineoplásica, Adult, Risk, Análisis de Supervivencia, Anciano, Antineoplastic Agents, Antibodies, Monoclonal/administration & dosage, Riesgo, Antibodies, Disease-Free Survival, PAZOPANIB, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Syöpätaudit - Cancers, Humans, Pyrroles, SYMPTOM INDEX, Carcinoma de Células Renales, Carcinoma, Renal Cell, Aged, Antineoplastic Combined Chemotherapy Protocol, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Pyrroles/administration & dosage, Carcinoma, UNTREATED MELANOMA, Renal Cell, Pirroles, Ipilimumab, Survival Analysis, Anciano de 80 o más Años, 1ST-LINE TREATMENT, Indole, Carcinoma, Renal Cell/drug therapy, Quality of Life, Calidad de Vida, INTERFERON-ALPHA, Neoplasias Renales

File Description: application/pdf; fulltext; STAMPA

Access URL: https://pubmed.ncbi.nlm.nih.gov/29562145
https://hdl.handle.net/20.500.12530/54277
https://researchers.mq.edu.au/en/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell
https://repositoriosaludmadrid.es/bitstream/20.500.12530/54277/1/29562145.pdf
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1712126
https://europepmc.org/articles/PMC5972549
https://trepo.tuni.fi/handle/10024/119785
https://moh-it.pure.elsevier.com/en/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell
https://trepo.tuni.fi/handle/10024/119785
https://biblio.ugent.be/publication/8730625
https://biblio.ugent.be/publication/8730625/file/8730628
http://hdl.handle.net/1854/LU-8730625
http://doi.org/10.1056/nejmoa1712126
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972549/pdf/nihms966108.pdf
https://doi.org/10.1056/NEJMoa1712126
https://pure.au.dk/portal/en/publications/9d613da7-a490-4e1e-940a-79cc1309b512
http://www.scopus.com/inward/record.url?scp=85045136401&partnerID=8YFLogxK

Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort

Authors: Soo Jung Lee Jin Hyung Kang Dae Ho Lee et al.

Contributors: Soo Jung Lee Jin Hyung Kang Dae Ho Lee et al.

Source: Cancer Res Treat

Subject Terms: Male, 0301 basic medicine, Melanoma/mortality, Antineoplastic Agents, Kaplan-Meier Estimate, Melanoma/drug therapy, Cohort Studies, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Immunological/administration & dosage, Immunological/adverse effects, Republic of Korea, Humans, Ipilimumab/administration & dosage, Molecular Targeted Therapy, Neoplasm Metastasis, Melanoma, Aged, Neoplasm Staging, Melanoma/diagnosis, Middle Aged, Ipilimumab, 3. Good health, Treatment Outcome, Ipilimumab/adverse effects, Original Article, Female, Immunological/therapeutic use, Ipilimumab/therapeutic use, Immunotherapy, Biomarkers

Access URL: http://www.e-crt.org/upload/pdf/crt-2016-024.pdf
https://pubmed.ncbi.nlm.nih.gov/27121719
https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.e21002
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266404
https://ir.ymlib.yonsei.ac.kr/bitstream/22282913/154108/1/T201700149.pdf
https://ir.ymlib.yonsei.ac.kr/handle/22282913/154108
https://snucm.elsevierpure.com/en/publications/ipilimumab-real-world-efficacy-and-safety-in-korean-melanoma-pati
https://pubmed.ncbi.nlm.nih.gov/27121719/
https://www.e-sciencecentral.org/articles/SC000021541

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Authors: Baas, P. Scherpereel, A. Nowak, A.K. et al.

Subject Terms: Aged, Antineoplastic Agents, Immunological/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Drug Therapy, Female, Humans, Ipilimumab/administration & dosage, Male, Mesothelioma, Malignant/drug therapy, Nivolumab/administration & dosage

Relation: The Lancet; https://iris.unil.ch/handle/iris/94699; serval:BIB_1562B775FCBE; 000614227700025

Availability: https://iris.unil.ch/handle/iris/94699
https://doi.org/10.1016/S0140-6736(20)32714-8

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.

Authors: Grasso, C.S. Tsoi, J. Onyshchenko, M. et al.

Source: Cancer cell, vol. 38, no. 4, pp. 500-515.e3

Subject Terms: Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cell Line, Tumor, Female, Gene Expression Profiling/methods, Humans, Immune Checkpoint Inhibitors/administration & dosage, Interferon-gamma/metabolism, Interferon-gamma/pharmacology, Ipilimumab/administration & dosage, Male, Melanoma/drug therapy, Melanoma/genetics, Melanoma/metabolism, Middle Aged, Nivolumab/administration & dosage, T-Lymphocytes/drug effects, T-Lymphocytes/metabolism, T-Lymphocytes/pathology, Transcriptome/drug effects, Transcriptome/genetics, Young Adult, RNA-seq, anti-CTLA-4, anti-PD-1, biopsies, clinical trial

Relation: info:eu-repo/semantics/altIdentifier/pmid/32916126; info:eu-repo/semantics/altIdentifier/eissn/1878-3686; https://serval.unil.ch/notice/serval:BIB_0C3D2E2E7DDD

Availability: https://serval.unil.ch/notice/serval:BIB_0C3D2E2E7DDD
https://doi.org/10.1016/j.ccell.2020.08.005

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma:Results From the Phase IIIb/IV CheckMate 511 Trial

Authors: Lebbé, Celeste Meyer, Nicolas Mortier, Laurent et al.

Source: Lebbé , C , Meyer , N , Mortier , L , Marquez-Rodas , I , Robert , C , Rutkowski , P , Menzies , A M , Eigentler , T , Ascierto , P A , Smylie , M , Schadendorf , D , Ajaz , M , Svane , I M , Gonzalez , R , Rollin , L , Lord-Bessen , J , Saci , A , Grigoryeva , E & Pigozzo , J 2019 , ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ' , Journal of Clinical Oncology , vol. 37 , no. 11 , pp. 867-875 .

Index Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Disease Progression, Double-Blind Method, Drug Administration Schedule, Female, Humans, Ipilimumab/administration & dosage, Male, Melanoma/drug therapy, Middle Aged, Neoplasm Staging, Nivolumab/administration & dosage, Progression-Free Survival, Skin Neoplasms/drug therapy, Time Factors, Young Adult, article